Calithera
Biosciences to Present Data at the 55th American Society for Hematology Annual
Meeting and the 2013 San Antonio Breast Cancer Symposium
Preclinical
Results for CB-839 Demonstrate Anti-Tumor Activity in Hematologic Malignancies
and Triple-Negative Breast Cancer
Full Press Release Follows.
SOURCE
Calithera Biosciences
|
SOUTH SAN FRANCISCO, Calif. , Nov. 26, 2013
/PRNewswire/ -- Calithera Biosciences, a biotechnology company focused
on the development of novel cancer therapeutics, today announced the
presentation of preclinical data for its lead anti-cancer therapeutic candidate,
CB-839, at two upcoming scientific conferences. CB-839 is a potent and
selective orally bioavailable glutaminase inhibitor that blocks the growth
and survival of many different types of cancer cells by interfering with
their metabolism of glutamine. Calithera plans to advance CB-839 into
Phase 1 clinical trials in patients with advanced solid and hematological
tumors in early 2014.
At the 55th American Society of
Hematology (ASH) Annual Meeting and Exposition in New Orleans, being held
December 7-10, 2013, Calithera will present data from in vitro and in
vivo studies evaluating CB-839 against diverse hematologic malignancies.
• Poster Presentation: Antitumor
Activity of the Glutaminase Inhibitor CB-839 in Hematological Malignancies
• Monday, December 9, 2013, 6:00 pm -
8:00 pm
• Session 802: Chemical Biology and
Experimental Therapeutics
• Abstract #4226
During the 2013 San Antonio Breast Cancer
Symposium, being held December 10-14, 2013, Calithera will present in
vitro and in vivo data on the anti-tumor activity of CB-839 in
triple-negative breast cancer models.
• Poster Presentation: Antitumor
Activity of the Glutaminase Inhibitor, CB-839, in Triple-Negative Breast
Cancer
• Thursday, December 12, 2013, 7:30 am
– 9:00 am
• Poster Session 2: Tumor Cell and
Molecular biology
• Abstract # P2-09-03
"The presentations at ASH and the SABC
Symposium will allow us to share the promising preclinical evidence of
antitumor activity for CB-839 in both liquid and solid tumor types where
glutaminase expression is believed to be a driver of tumor growth," said
Susan Molineaux, PhD, President and Chief Executive Officer of
Calithera Biosciences. "Based on these results, we are looking
forward to initiating clinical studies for CB-839 early next year."
About Calithera Biosciences
Calithera is discovering and developing novel
small molecule oncology therapeutics that inhibit pathways critical to tumor
growth and survival. The Calithera team has the experience and the
ability needed to discover novel therapeutics and advance these discoveries
through clinical development. The company is applying this expertise to
build a pipeline of anti-cancer compounds that are distinct from other
oncology therapeutics. Calithera's lead clinical candidate, CB-839,
blocks glutaminase, an enzyme critical to tumor metabolism, and is poised to
enter Phase 1 clinical testing. Calithera Biosciences is a privately
held company located in South San Francisco, CA. For more information,
please visit www.calithera.com .
SOURCE Calithera Biosciences
CONTACT: Susan M. Molineaux, PhD, President and
CEO, Calithera Biosciences, info@calithera.com, BCC Partners, Karen L.
Bergman or, Michelle Corral, 650.575.1509, 415.794.8662
Web Site: http://www.calithera.com
|
 |
No comments:
Post a Comment